Forward Pharma traded at $4.35 this Friday July 1st, decreasing $0.15 or 3.33 percent since the previous trading session. Looking back, over the last four weeks, Forward Pharma lost 15.70 percent. Over the last 12 months, its price fell by 47.46 percent. Looking ahead, we forecast Forward Pharma to be priced at 4.18 by the end of this quarter and at 3.72 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Avrobio Inc 0.93 0.01 1.25% -89.04%
Biogen 210.88 0.25 0.12% -38.86%
Bioline Rx 1.26 -0.04 -3.08% -58.96%
DBV Technologies 2.51 0.12 5.02% -54.86%
Forward Pharma 4.35 -0.15 -3.33% -47.46%
Idera Pharmaceuticals 0.42 -0.01 -3.08% -62.43%

Indexes Price Day Year
USND 11183 55.59 0.50% -23.73%

Forward Pharma
Forward Pharma A/S is a Denmark-based bio-pharmaceutical company. It is developing a proprietary formulation of dimethyl fumarate (DMF), for the treatment of multiple sclerosis (MS) and other inflammatory and neurological indications. DMF is an immunomodulator that can be used as a therapeutic to improve the health of patients with MS and immune disorders .The Company is headquartered in Copenhagen, Denmark.